Stagnant R&D Spending May Restrict Growth of Global Pharma Giants in 2017

☞ | View the text of this post. Exclusively available to ASQ Members.

The overall growth of 15 leading global pharma companies may come under pressure soon as their research and development (R&D) spending has not shown any positive results. Although their R&D expenditures are growing and many products are in several stages of clinical trials, not many new molecules are expected to be blockbusters. These companies failed to launch any new blockbuster, sales over $1 billion, product during the first half of 2017. The cost of new